Tarsus Pharmaceuticals Set to Unveil Financial Results
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is gearing up to present its financial results for the fourth quarter and the full year of 2024. The company will host a live webcast to share insights and updates, scheduled for Tuesday, February 25, 2025. Set to start at 5:00 a.m. PT / 8:00 a.m. ET, this event will mark an important occasion for investors and stakeholders alike.
Accessing the Live Webcast
Those interested in the financial results can tune into the live webcast, where Tarsus will discuss their performance and strategies moving forward. A recorded version will be available shortly after the presentation, allowing everyone to catch up on the valuable information shared.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. focuses on innovative solutions in healthcare, leveraging cutting-edge science and technology to enhance treatment options. The company primarily concentrates on eye care, aiming to address significant unmet medical needs. Its flagship product, XDEMVY (lotilaner ophthalmic solution, 0.25%), has received FDA approval for treating Demodex blepharitis, showcasing Tarsus's commitment to improving patient outcomes.
Pipeline Developments
In addition to XDEMVY, Tarsus is actively developing other promising therapies, namely TP-04, aimed at treating Ocular Rosacea, and TP-05, which is designed as an oral tablet for the potential prevention of Lyme disease. These developments highlight their dedication to addressing various therapeutic areas, particularly within eye care and infectious diseases.
Media and Investor Relations
Tarsus provides various channels for media inquiries and investor relations. Adrienne Kemp serves as the Sr. Director of Corporate Communications and can be reached directly for media-related questions. For inquiries regarding investments, David Nakasone, the Head of Investor Relations, is available to assist. Both contacts embody the transparency Tarsus promotes.
Commitment to Patient Care
Through its commitment to advanced research and development, Tarsus Pharmaceuticals exemplifies a mission-driven approach to healthcare. The company’s ambition is to ensure that those who rely on their products receive effective treatments that significantly improve their quality of life. As they prepare for the upcoming financial results announcement, stakeholders are keenly anticipating further details on their progress and future direction.
Frequently Asked Questions
What financial results will Tarsus announce?
Tarsus will report its fourth quarter and full-year 2024 financial results during the webcast.
When is the webcast scheduled?
The webcast is set for February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET.
Where can I access the recorded webcast?
A recorded version of the webcast will be available on Tarsus's website shortly after the live event.
What is XDEMVY?
XDEMVY is an ophthalmic solution approved by the FDA for the treatment of Demodex blepharitis.
Who can I contact for media inquiries?
Adrienne Kemp, Sr. Director of Corporate Communications, is the contact person for media inquiries at Tarsus Pharmaceuticals.
